(Total Views: 209)
Posted On: 03/19/2019 1:38:02 PM
Post# of 149716
Thanks for the info and reference Fortuno! That is more discouraging than I had hoped.
So, if I understand these agreements correctly we will owe 'up to' 12.5% of net sales. How is the 'up to' determined? If there is no cap to the sales amount, ABBV and PGNX may end up making more from leronlimab than CytoDyn??
I hope I am not familiar enough with these agreements and misunderstanding something.
So, if I understand these agreements correctly we will owe 'up to' 12.5% of net sales. How is the 'up to' determined? If there is no cap to the sales amount, ABBV and PGNX may end up making more from leronlimab than CytoDyn??
I hope I am not familiar enough with these agreements and misunderstanding something.
(0)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
